These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35699175)

  • 21. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
    Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773).
    Kołtowski Ł; Aradi D; Huczek Z; Tomaniak M; Sibbing D; Filipiak KJ; Kochman J; Balsam P; Opolski G
    Kardiol Pol; 2016; 74(4):372-9. PubMed ID: 26365936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
    Zheng W; Li Y; Tian J; Li L; Xie L; Mao Q; Tong W; Zhou D; Azzalini L; Zhao X
    Biomed Res Int; 2019; 2019():3170957. PubMed ID: 31016189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the
    Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
    Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
    Hamilos M; Petousis S; Xanthopoulou I; Goudevenos J; Kanakakis J; Sitafidis G; Vavouranakis M; Skalidis E; Kochiadakis G; Lekakis J; Vardas PE; Alexopoulos D
    Coron Artery Dis; 2018 Jan; 29(1):53-59. PubMed ID: 28834792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
    Clarkson SA; Heindl B; Cai A; Beasley M; Dillon C; Limdi N; Brown TM
    Am J Cardiol; 2021 Jun; 148():1-7. PubMed ID: 33667441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Impact of
    Kim JH; Lee SJ; Cha JJ; Park JH; Hong SJ; Ahn TH; Kim BK; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Jeong YH; Kim HS; Kim MH; Shin ES; Lim DS;
    J Am Heart Assoc; 2024 May; 13(10):e032248. PubMed ID: 38761068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.
    Vogel B; Baber U; Cohen DJ; Sartori S; Sharma SK; Angiolillo DJ; Farhan S; Goel R; Zhang Z; Briguori C; Collier T; Dangas G; Dudek D; Escaned J; Gil R; Han YL; Kaul U; Kornowski R; Krucoff MW; Kunadian V; Mehta SR; Moliterno D; Ohman EM; Sardella G; Witzenbichler B; Gibson CM; Pocock S; Huber K; Mehran R
    JAMA Cardiol; 2021 Sep; 6(9):1032-1041. PubMed ID: 33991416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
    Bossard M; Granger CB; Tanguay JF; Montalescot G; Faxon DP; Jolly SS; Widimsky P; Niemela K; Steg PG; Natarajan MK; Gao P; Fox KAA; Yusuf S; Mehta SR
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29101117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice.
    Mullen L; Meah MN; Elamin A; Aggarwal S; Shahzad A; Shaw M; Hasara J; Rashid M; Fisher M; Ali T; Patel B; Ding WY; Grainger R; Heseltine T; Kirmani BH; Obeidat M; Kasolo Y; Thatchil J; Khand A
    J Am Heart Assoc; 2021 Apr; 10(8):e019467. PubMed ID: 33834845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
    Sibbing D; Gross L; Trenk D; Jacobshagen C; Geisler T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Parma R; Felix SB; Neumann FJ; Hausleiter J; Baylacher M; Koltowski L; Mehilli J; Huber K; Huczek Z; Aradi D; Massberg S;
    Eur Heart J; 2018 Aug; 39(29):2749-2758. PubMed ID: 29912422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
    Biswas M; Kali SK
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1147-1159. PubMed ID: 33523336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
    Wang T; Li H; Wang F; Sun L; Yu L
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1679-1686. PubMed ID: 34164723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.
    Yu L; Wang T; Bai H; Zhu W; Li Y; Wu J; Liu W; Sun L; Yu A; Li H
    BMC Cardiovasc Disord; 2021 Aug; 21(1):391. PubMed ID: 34384383
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Beitelshees AL; Thomas CD; Empey PE; Stouffer GA; Angiolillo DJ; Franchi F; Tuteja S; Limdi NA; Lee JC; Duarte JD; Kreutz RP; Skaar TC; Coons JC; Giri J; McDonough CW; Rowland R; Stevenson JM; Thai T; Vesely MR; Wellen JT; Johnson JA; Winterstein AG; Cavallari LH; Lee CR;
    J Am Heart Assoc; 2022 Feb; 11(4):e024159. PubMed ID: 35156424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial.
    Mehran R; Chandrasekhar J; Urban P; Lang IM; Windhoevel U; Spaulding C; Copt S; Stoll HP; Morice MC;
    JAMA Cardiol; 2020 Aug; 5(8):939-947. PubMed ID: 32432718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.